
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES227
Post hoc analysis found no significant difference among the 5,197 diabetic patients included in
the MATCH trial in terms of the incidence of primary endpoint. Level 1++

[@Diener_2004]

